Human pancreatic islet cells and hepatocytes represent the two most likely target cells for genetic therapy of type I diabetes. However, limits to the efficiency of rAAV serotype 2 (rAAV2)-mediated gene transfer have been reported for both of these cell targets. Here we report that nonserotype 2 AAV capsids can mediate more efficient transduction of islet cells, with AAV1 being the most efficient serotype in murine islets, suggesting that receptor abundance could be limiting. In order to test this, we generated rAAV particles that display a ligand (ApoE) that targets the low-density lipoprotein receptor, which is present on both of these cell types. The rAAV/ApoE viruses greatly enhanced the efficiency of transduction of both islet cells ex vivo and murine hepatocytes in vivo when compared to native rAAV2 serotype (220-and four-fold, respectively). The use of receptor-targeted rAAV particles may circumvent the lower abundance of receptors on certain nonpermissive cell types.
Introduction
The pancreatic islets of Langerhans are critical for glucose homeostasis and their loss in type I diabetes mellitus results in a disease that greatly increases the morbidity and mortality of affected individuals. 1 Islet cell transplantation has provided an approach to the long-term remediation of the condition. [2] [3] [4] However, the current paradigm of cadaveric donor-derived islet cell transplantation creates a scenario in which allograft immunity compounds pre-existing autoimmunity leading to islet cell destruction. While certain newer immunosuppressive protocols appear to be better tolerated, 5 it would be highly desirable to enhance islet cell engraftment while decreasing immunosuppressive therapy. This could potentially be accomplished by genetically manipulating the islets to express antiinflammatory cytokines or other mediators that could act locally to decrease the immune response to the allograft and enhance cell viability. 6 Alternatively, insulin gene transfer into hepatocytes in vivo could provide an alternative source of glucose-sensitive insulin release in insulin-deficient type I diabetics.
Our group previously demonstrated the potential of rAAV for such a purpose. Specifically, rAAV was used to deliver reporter genes and potentially therapeutic cytokines, such as IL-4 and IL-10, within human and murine islet cells. 7 This study was encouraging since it also indicated that rAAV-transduced islet cells retain their normal glucose-stimulated insulin response. However, very high multiplicities of infection (MOIs), as high as 10 000 infectious units (i.u.) per cell, were required in those studies in order to observe ex vivo transduction with serotype 2-derived rAAV vectors. In the current study, we sought to enhance rAAV-mediated transduction by using alternative promoters, such as the human insulin promoter, alternative serotypes, and rAAV capsid mutants that incorporate a ligand derived from apolipoprotein E (ApoE) that is targeted to the low-density lipoprotein receptor (LDL-R) 8 . These studies indicate that the transduction efficiency can be enhanced 220-fold, allowing for the use of MOIs as low as 5 i.u. per cell. The utility of the targeted vectors was also demonstrated for in vivo gene transfer by portal vein injection, where a four-fold enhancement of transgene expression was observed. Taken collectively, these modifications render the use of rAAV for islet cell transduction substantially more feasible and suggest a strategy for enhancing rAAV-mediated gene delivery to other cells or tissues that are relatively nonpermissive.
Results

Optimization of transcriptional Activity
Previous studies of rAAV-mediated islet cell transduction have utilized either the cytomegalovirus (CMV) immediate early promoter or the CMV enhancer/chicken beta actin hybrid promoter (CB). 7 In order to determine whether the transcriptional activity of the rAAV vector cassette could be further enhanced, a series of reporter gene constructs were prepared, utilizing a translational fusion between the firefly luciferase gene and the enhanced yellow fluorescent protein (luc-EYFP). The following promoters were evaluated, CMV, CB, elongation factor 1-alpha (E1a), and the human insulin promoter (Ins) (Figure 1 ). Human islet cells were transfected using Lipofectamine 2000 TM . Expression was measured 48 h later by luminometry. As shown in the figure (Figure 2) , the human insulin promoter was, by far, the most efficient promoter tested, mediating expression levels at least 10-fold higher than those obtained with the CMV or CB promoters. The effect was the same whether or not islets underwent additional treatment with trypsin to enhance penetration of liposomes.
Evaluation of Different rAAV serotypes
Different serotypes of AAV bind to different cell surface receptors, including heparan sulfate proteoglycan for AAV2 and AAV3, 9 O-linked sialic acid for AAV4, 10 and N-linked sialic acid for AAV5. 11, 12 In addition, the intracellular trafficking may vary among the different serotypes in different cells. 13, 14 In our initial experiments to compare islet cell transduction efficiency of the various serotypes, we utilized a CB-promoter-driven human alpha 1-antitrypsin (CB-hAAT) cassette ( Figure 1 ) as a secreted reporter to transduce murine islets in culture. As shown in the figure, the level of hAAT expression achieved 6 days after transduction was substantially higher with vector packaged in AAV1 capsids as compared with the other serotypes ( Figure 3 ).
The density and composition of cell surface receptors can differ significantly between species. Therefore, we sought to confirm the above findings with human islets, in this instance using the green fluorescent protein (GFP) as a reporter. Confocal microscopy revealed no enhancement of gene expression from alternative AAV serotypes in human islets ( Figure 4 ). This is in contrast with a marked preference for rAAV1 shown above in murine islets ( Figure 3) . The difference in transduction efficiency between serotypes suggests that receptor binding is a limiting step for transduction of islets. Linear maps of the rAAV constructs used for ex vivo transduction of human and murine islets are depicted. ITR¼AAV2 inverted terminal repeat, A n ¼polyadenylation signal, lucEYFP¼translational fusion between firefly luciferase and the enhanced yellow fluorescent protein, hAAT¼the human alpha 1-antitrypsin coding sequence, EF¼human elongation factor 1 alpha promoter, CMV¼human cytomegalovirus immediate early enhancer/promoter, a hybrid construct with the CMV enhancer only followed by the chicken beta actin promoter and a hybrid intron (upstream half of beta actin, downstream half of rabbit beta globin) is also shown. In order to evaluate the potential limitation to rAAV vector transduction that might be mediated by capsid binding to the cell surface, we packaged rAAV2 vector genomes into a number of alternative capsids, including AAV serotype 1, 3, 4, and 5 capsids 15 and rAAV2 capsids into which the 28-amino acid ApoE-derived ligand was inserted. Our group has previously identified residues within the AAV2 capsid into which new peptides can be inserted, thus allowing one to target specific receptors without disrupting the integrity of the capsid. 16 In order to target the LDL-R on islets, we inserted a ligand derived from ApoE 8,17 into a site one residue downstream from the N-terminal methionine of VP2 ( Figure  5a ) as described in the Experimental Protocol. Since VP1 simply represents an N-terminal extension of VP2, this new peptide will be displayed both within VP1 and VP2. Two different reporters were packaged within the rAAV2-ApoE capsids, a human insulin promoter-driven GFP (Ins-GFP) cassette and the same CB-hAAT cassette described above. In the GFP transduction experiments, the ApoE capsid appeared substantially more efficient for islet cell transduction (Figure 5b) , with a greater number of cells demonstrating native GFP fluorescence within each islet examined.
The enhancement of transduction was quantified in the hAAT expression experiments. Equal volumes of CBhAAT packaged into either wild-type (wt) AAV2 capsids or AAV2-ApoE capsids were used to infect murine islet cells and the release of hAAT into the supernatant medium was measured at 6 and 12 days by enzymelinked immunoassay (ELISA). As shown in figure  (Figure 6 ), the transduction efficiency was 90-fold greater (945 versus 11 ng/ml) with the ApoE insert. When the infectious titer of this vector was taken into account, however, the relative transduction efficiency in terms of expression/infectious MOI was approximately 9000-fold greater (MOI 5.5 versus 537.5) with the ApoE capsid ( Table 1 ). This degree of enhancement is deduced since an equal volume of a stock with a 100-fold lower infectious titer was used to generate 90-fold greater hAAT expression. Even if one makes the most conservative assessment of the enhancement factor, considering the physical titer rather than the infectious titer, the expression/particle was enhanced by 220-fold (4300 particles versus 10 000 particles), since the ApoE stock had a physical particle titer 2.3-fold lower than the wt AAV1 AAV2 AAV5 Figure 4 Relative transduction efficiency of various rAAV serotypes in human islets. CMV-enhancer/chicken beta actin promoter-driven expression of the green fluorescent protein (GFP) was accomplished with vector packaged into either AAV serotype 1, 2, or 5 capsids. Confocal microscopy was performed at 3 days post-transduction. (Table 1) . Vector preparations were characterized in terms of their physical titer by both DNA dot-blot hybridization and by Taqman s real-time PCR, and in terms of their biological titer by infectious center assay on C12 cells (an AAV-Rep-expressing Hela cell line). A modest decrease in packaging efficiency was noted with some of these constructs. The interpretation of infectious center assay data is difficult to interpret in this context, since the abundance of the various receptors on these cells has not been characterized. However, it is important to note that the mutation site is far removed from the heparin binding domain and so should not create direct steric interference with the native uptake pathway. The infectious center data are included since the particle to infectious unit ratio can serve as an indicator of partially assembled or unstable vector particles. 16 Taken together, these data convincingly demonstrate that receptor targeting can greatly enhance rAAV transduction, regardless of the promoter or reporter gene system used.
Enhancement of in vivo transduction by targeting the LDL-R
In order to determine whether LDL-R targeting would enhance gene transfer and expression in vivo, we injected the portal veins of C57Bl6 mice with equal physical particle titer doses of rAAV-CB-hAAT packaged into wt AAV2 or ApoE-ligand containing capsids, and examined serum hAAT levels at timed intervals up to 5 weeks after injection. As expected from previous studies, the lower dose of 7.5 Â 10 9 physical particles of the native capsid resulted in no detectable hAAT expression (Figure 7 ), while this dose of targeted vector mediated significantly higher levels. At the 10-fold higher dose, the expression of targeted vector was found to be four-fold higher than that of the standard rAAV2 vector. It should be noted that these doses were approximately 100-fold lower than those previously reported by our group for optimal in vivo rAAV2-mediated transduction of hepatocytes.
Blocking of transduction by competition with excess ApoE protein
In order to show that the ApoE ligand is mediating the viral targeting via the LDL-R, we infected several cell lines in the presence or absence of the specific ligand ( Figure 8 ). The ApoE ligand is inserted in the amino terminus of VP2 and does not alter the normal heparin sulfate proteoglycan binding site, which has been 
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SA Loiler et al mapped to amino acids 585. 16 Therefore, we anticipated competitive inhibition by either soluble heparin or soluble ApoE. In addition, soluble heparin has been shown to bind effectively to ApoE protein. 18, 19 As predicted, soluble heparin effectively blocked AAV2/ ApoE virus from using the normal AAV2 heparin binding site or the ApoE ligand to infect 293, COS7, or HepG2 cells (Figure 8a, b, c) . The recombinant ApoE protein significantly blocked AAV2/ApoE virus from infecting 293 and COS7 cells (Figure 8a, b) and moderately blocked the infection of HepG2 cells ( Figure  8c ). The nonspecific protein bovine serum albumin (BSA) had no effect on the AAV2/ApoE infection of any of the cells tested. Figure 8d shows that the ApoE protein had no effect on wt AAV2 capsid infection of 293 cells. These data show the specific ligand interactions of the AAV2/ ApoE virus that facilitate infection of various cell lines.
Discussion
Previous work from our group has demonstrated the utility of rAAV for long-term expression with a minimum of vector-related side effects. The performance profile of this vector system in human islets was somewhat mixed; however, since very high MOIs were needed for efficient transduction. 7 In this report, we have demonstrated a greatly enhanced transduction efficiency either by increasing expression with more active promoters or by increasing cell attachment and uptake in a very specific manner, targeting the LDL receptor family with a peptide derived from ApoE. The latter capsid yielded vector preparations with modestly reduced titer (approximately 10-fold lower than wt), but resulted in a dramatic enhancement of transduction efficiency (220-fold as judged by physical titer).
Several groups have reported the use of receptor targeting in the context of rAAV in the recent past. 16, [20] [21] [22] [23] Previously, cell types that have been targeted include hematopoietic progenitors, 24 bronchial epithelial cells, 16 and endothelial cells. 22 The current report represents the greatest increase in transduction efficiency yet observed from such a capsid modification, and further demonstrates the in vivo utility of this approach. The sites within AAV where inserts have been successfully placed have generally clustered near the N-terminus 16 and within the putative heparin binding domain (especially positions I587 or R588). 22 In general, these capsid mutants have a mildly decreased packaging efficiency, as was noted with the ApoE insert. 
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The specificity of the ApoE targeting effect was demonstrated by competition experiments in which ApoE protein competitively inhibited transduction by these viruses, while nonspecific protein (albumin) did not. Soluble heparin also inhibited, as predicted, since it is capable of competing for binding at both the LDL-R on the target cell and the heparin binding site on the AAV capsid. The magnitude of inhibition by ApoE was relatively modest in the immortalized cell lines where competition was tested. Unfortunately, islets were not available for these additional studies. One might have anticipated a greater degree of inhibition of transduction with soluble ApoE in islets where the relative transduction enhancement suggests a much higher percentage of transduction is because of entry through the LDL-R pathway. It is important to note that ApoE is a ligand for the entire LDL receptor family, so that it has not been proven that the enhancement of delivery to islets and to the murine liver was due to the LDL-R itself. There are cell lines available that are deficient for LDL-R, and these might have been used to further delineate the specificity of the interaction. However, even if the effect were mediated by a receptor other than LDL-R itself, it would still be safe to conclude that the ApoE ligand does enhance uptake via a receptor that is present on pancreatic islets and murine liver, which is most likely a member of the LDL-R family.
The relative enhancement by use of AAV1 in mouse islets is most likely because of targeting of different receptors. However, it is also possible that the capsid variants could affect other factors such as the internalization of vector, nuclear targeting or nuclear entry. It is also worth noting the species-related differences in serotype preferences. AAV1 capsid was clearly superior to AAV2 in murine islets, while this was not the case in human islets. This illustrates one potential advantage of targeting a specific receptor known to be in high abundance on the islet cell across species, like the LDL-R. In making these comparisons, we have chosen the most conservative method of comparing physical particle titers. It should be noted, however, that non-native capsids could affect particle stability and infectivity in a fashion that might be reflected in a truly altered particle to infectious unit ratio. Therefore, we have presented infectious titer information as well.
The use of the human insulin promoter was also found to have a significant advantage in the overall efficiency of transgene expression. This result has been reported previously by Yang and Kotin. 25 In the latter report, the insulin promoter was shown to be glucose sensitive. While our studies did not evaluate the glucose responsiveness of our constructs, this feature represents a potential mechanism for regulation of the production of therapeutic molecules. The relative specificity of the insulin promoter for beta cells also adds another level of precision to the gene delivery process, in that other cells transduced with insulin promoter-driven constructs are not likely to express the transgene at significant levels. It is also unlikely that the insulin promoter will undergo transcriptional silencing [26] [27] [28] [29] in beta cells of the pancreatic islets, although it is possible that the promoter cassette could be selectively silenced in the context of the vector, while the endogenous insulin promoter remains active in the context of its chromosomal locus. Overall, these studies make it much more practical to consider ex vivo islet cell transduction in the context of islet cell transplantation. The candidate genes that might be considered in such a context include IL-10, IL-1 receptor antagonist, antioxidants (such as heme oxygenase and Mn SOD), and inhibitors of apoptosis. 30 It is still unclear which of these gene products alone or in combination might be most beneficial in this context.
Finally, this work demonstrates a potential benefit from using targeted vector after in vivo delivery to the portal vein in mice. While we have worked under the hypothesis that our results indicate increased efficiency of hepatocyte transduction, LDL-R is present on other cell types as well, including vascular endothelial cells. If the enhanced overall protein expression is mediated by increased delivery to hepatocytes, these vectors could provide valuable tools for studying the observed limitations to rAAV2-mediated gene transfer in the liver.
Experimental Protocol Plasmid constructs and rAAV packaging
The rAAV serotype 2 (rAAV2) vector plasmids used for these experiments are depicted diagrammatically ( Figure  1) . Briefly, the CMV-beta-actin promoter from pCBhAAT, 31 the elongation factor promoter and the human insulin promoter were cloned into the KpnI and HindIII sites of pTR-CMV-lucEYFP (gift from Dr B Byrne) replacing the CMV promoter. The rAAV-ApoE construct was made by inserting an oligonucleotide that coded for the human Apo E amino acids LRKLRKRLLR and DWLKAFYDKVAEDLDEAF, which code for the hApoE LDL-receptor ligand and the lipid-associated peptide, respectively, immediately after amino acid 138 of the VP1 coding sequence. The Apo E oligonucleotide was flanked by the restriction sites for EagI and MluI and was inserted into the plasmid pIM45-EM138-ApoE. pIM45 was described previously and consists of the AAV nucleotides coding for the rep and cap genes but is missing the terminal repeats. 32 To construct pIM45-EM138, site-directed mutagenesis was used to insert an EagI/MluI cloning site immediately after amino-acid position 138 of the VP1 coding sequence, which is also immediately after the initiator threonine codon of VP2. The oligo: 5-AGGAACCTGTTAAGACGCGGCCGACG CGTGCTCCGGGAAAAAAGAG-3 and its complement were used to insert the EagI/MluI restriction site and the resulting pIM45-EM138 plasmid was sequenced to insure no fortuitous mutations were introduced. The net effect was that pIM45-EM138-ApoE contains the ApoE-receptor ligand and lipid-associated peptide flanked by RP and TR (coded by the EagI and MluI sites), inserted immediately after the threonine start codon for VP2, which is immediately after amino acid 138 of VP1.
rAAV production was performed as previously described. 33 The method involves cotransfection with two plasmids by calcium phosphate coprecipitation of a permissive human cell line (HEK293). HEK293 cells were grown as monolayers (initially seeded with 6 Â 10 8 cells per Nunc r cell factory) in Dulbecco's modified minimal essential media (DMEM) containing 10% fetal bovine serum (371C, 5% CO 2 ). After 18 h, the cells were transfected with different pairs of plasmids. The first nonrescuable helper plasmid (pDG) contained the . Crude lysates were clarified by centrifugation with virus-containing supernatant purified by iodixanol density gradient centrifugation, followed by heparin affinity chromatography and concentration. Purity of preparations was determined by subjection of a sample to silver-stained SDS-PAGE. Infectious center assays were used to determine the rAAV titer, and dot blot assays were performed to quantify the titer of the rAAV physical particles and then confirmed by real-time PCR. The latter values were used to calculate the particle-to-infectivity ratio. 33 rAAV-ApoE virus was prepared in essentially the same way except that the helper plasmids used were pIM45-EM138-ApoE (to provide a capsid that contained the ApoE ligand inserted into aa position 138 of VP1) and pXX6 34 to provide the adenovirus helper functions.
Human and murine islet cell cultures
Pancreatic islet cells were isolated as previously described. 7 Briefly, after intraductal injection of a solution containing Liberase (Boehringer-Mannheim Biochemicals, Indianapolis, IN, USA), a whole human pancreas was subjected to mechanical shaking, and aliquots of eluate were withdrawn at various points during a 2-h period. Purification of the final islet preparation was obtained by centrifugation on discontinuous Eurocollins-Ficoll gradients followed by hand picking. Mouse islets (C57Bl/6; Jackson Research Laboratories, Bar Harbor, ME, USA) were obtained through intraductal injection of collagenase type XI solution (Sigma, St Louis, MO, USA), followed by purification through repeated washings and hand picking. Islets were maintained in standard culture conditions (CMRL Medium-1066 with 10% fetal bovine serum; 5% CO 2 , 371C; D-glucose concentration¼3.33 mM). Islet purity was assessed by diphenylthiocarbazone staining, and viability was determined by staining with propidium iodide and fluorescein diacetate.
Transduction and detection of gene expression
Intact islets, maintained as previously indicated at concentrations of 0.2-1 Â 10 3 , were transduced at an MOI of 5-10 000 i.u. per cell of the appropriate rAAV construct. Islet equivalents were determined for all pancreatic isolations; an estimate of 2000 cells per islet equivalent was used for all calculations. Specifically, an islet equivalent (ie, a combination measure of size and number) was defined as an islet that was spherical in shape and 150 mm in diameter; an appropriate algorithm was used to calculate the islet equivalent number. Using this islet equivalent value, we have used 2 Â 10 4 -2 Â 10 7 i.u. of rAAV per islet equivalent, which equates to an MOI of 10-10 000 i.u. per islet cell. Infections of islet cells were performed in 16-well chamber slides. 
Portal vein injection of rAAV vectors
All animal procedures were performed with prior approval of the University of Florida Institutional Animal Care and Use Committee. Young adult, 25-g C57Bl6 mice were anesthetized with isoflorane inhalation and underwent laparatomy under aseptic conditions. The portal vein was directly visualized and vector was injected through a 29-gauge stainless steel needle. The laparatomy incision was closed and the animals were allowed to recover. Serial tail vein phlebotomies were performed at biweekly intervals, and human AAT was measured using a species-specific ELISA.
Competition experiment
Cells (2.0 Â 10 5 ) were plated on each well of a 16-well chamber slide. Cells were incubated with PBS alone or with one of the indicated inhibitor molecules for 30 min prior to infection. Particles (2.0 Â 10 9 ) of the indicated virus were then added to the chamber slides and allowed to incubate overnight. The media was changed after 12 h. At 48 h postinfection, the cells were lysed with cell culture lysis reagent (Promega) and assayed for luciferase activity (Promega). Inhibitors: 10 mg/well Heparin (Sodium salt, grade I-A, Sigma, H-3149) in PBS, Human recombinant Apolipoprotein E3 (Panvera, P2003) 1 mg/ well, BSA (New England Biolabs) 1mg/well.
